Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a crossover study of PF-00489791 for Raynaud's phenomenon
2010-019009-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00489791 in Raynaud disease and Primary Raynaud phenomenon (2 arms), sponsored by Pfizer. Primary endpoint: Change in Raynaud Condition Score. Started May 2010; status: completed.
02
Drugs
PF-00489791
03
Conditions
Raynaud diseasePrimary Raynaud phenomenon
Beyond the preview
Go deeper on 2010-019009-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019009-40.